These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36330485)

  • 1. Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.
    Chen Z; John J; Wang JH
    Front Oncol; 2022; 12():995434. PubMed ID: 36330485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
    Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
    J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
    John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
    Front Immunol; 2022; 13():992630. PubMed ID: 36330507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
    John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
    Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.
    Shivarudrappa AH; John J; Vashisht M; Ge H; Liu S; Chen J; Siddoway K; Dong R; Chen Z; Wang JH
    Front Immunol; 2024; 15():1405318. PubMed ID: 39055715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15
    Chen SMY; Li B; Nicklawsky AG; Krinsky AL; Brunetti T; Woolaver RA; Wang X; Chen Z; Young CD; Gao D; Wang XJ; Wang JH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32916850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.
    Muijlwijk T; Nijenhuis DNLM; Ganzevles SH; Brink A; Ke C; Fass JN; Rajamanickam V; Leemans CR; Koguchi Y; Fox BA; Poell JB; Brakenhoff RH; van de Ven R
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor immune microenvironment in head and neck cancers.
    Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
    Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
    Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
    Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
    Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
    Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas.
    Sánchez-Canteli M; Juesas L; Garmendia I; Otero-Rosales M; Calvo A; Alvarez-Fernández M; Astudillo A; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why the Outcome of Anti-Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers.
    Wang JH
    Bioessays; 2020 Oct; 42(10):e2000024. PubMed ID: 32767371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlate the
    Lyu H; Li M; Jiang Z; Liu Z; Wang X
    Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
    Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
    J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy.
    Canning M; Guo G; Yu M; Myint C; Groves MW; Byrd JK; Cui Y
    Front Cell Dev Biol; 2019; 7():52. PubMed ID: 31024913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
    Zhou L; Zeng Z; Egloff AM; Zhang F; Guo F; Campbell KM; Du P; Fu J; Zolkind P; Ma X; Zhang Z; Zhang Y; Wang X; Gu S; Riley R; Nakahori Y; Keegan J; Haddad R; Schoenfeld JD; Griffith O; Manguso RT; Lederer JA; Liu XS; Uppaluri R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.